Search by Drug Name or NDC

    NDC 00067-8129-08 Theraflu ExpressMax 650; 25; 10 mg/30mL; mg/30mL; mg/30mL Details

    Theraflu ExpressMax 650; 25; 10 mg/30mL; mg/30mL; mg/30mL

    Theraflu ExpressMax is a ORAL SYRUP in the HUMAN OTC DRUG category. It is labeled and distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. The primary component is ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 00067-8129
    Product ID 0067-8129_515a0df6-7148-4edc-bfb8-aa1a036d436b
    Associated GPIs 43994003900930
    GCN Sequence Number 063195
    GCN Sequence Number Description diphenhyd/phenyleph/acetaminop LIQUID 25-650/30 ORAL
    HIC3 B3O
    HIC3 Description 1ST GEN ANTIHISTAMINE-DECONGESTANT-ANALGESIC COMB
    GCN 98952
    HICL Sequence Number 035433
    HICL Sequence Number Description DIPHENHYDRAMINE HCL/PHENYLEPHRINE HCL/ACETAMINOPHEN
    Brand/Generic Generic
    Proprietary Name Theraflu ExpressMax
    Proprietary Name Suffix Nighttime Severe Cold and Cough
    Non-Proprietary Name Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl
    Product Type HUMAN OTC DRUG
    Dosage Form SYRUP
    Route ORAL
    Active Ingredient Strength 650; 25; 10
    Active Ingredient Units mg/30mL; mg/30mL; mg/30mL
    Substance Name ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2024-12-31

    Package

    NDC 00067-8129-08 (00067812908)

    NDC Package Code 0067-8129-08
    Billing NDC 00067812908
    Package 245.5 mL in 1 BOTTLE (0067-8129-08)
    Marketing Start Date 2015-07-15
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL f5a66541-1b15-4dfe-91e0-d8d5f8fdc7fb Details

    Revised: 4/2022